| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 8526 | 2011 |
| Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ... New England Journal of Medicine 382 (20), 1894-1905, 2020 | 5915 | 2020 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3733 | 2016 |
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Côté, ... Cancer research 66 (8), 3992-3995, 2006 | 2862 | 2006 |
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2542 | 2014 |
| Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 JP Gérard, T Conroy, F Bonnetain, O Bouché, O Chapet, ... Journal of clinical oncology 24 (28), 4620-4625, 2006 | 2243 | 2006 |
| KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008 | 1977 | 2008 |
| Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Ducreux, AS Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, ... Annals of oncology 26, v56-v68, 2015 | 1640 | 2015 |
| Immunogenic death of colon cancer cells treated with oxaliplatin A Tesniere, F Schlemmer, V Boige, O Kepp, I Martins, F Ghiringhelli, ... Oncogene 29 (4), 482-491, 2010 | 1277 | 2010 |
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005 | 1275 | 2005 |
| EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma EO for Research, European Association for the Study of the Liver Journal of hepatology 56 (4), 908-943, 2012 | 1145 | 2012 |
| Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma AL Cheng, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, HY Lim, M Kudo, ... Journal of hepatology 76 (4), 862-873, 2022 | 1116 | 2022 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of Oncology 29, iv238-iv255, 2018 | 1016 | 2018 |
| Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 880 | 2009 |
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus … U Vanhoefer, P Rougier, H Wilke, MP Ducreux, AJ Lacave, E Van Cutsem, ... Journal of Clinical Oncology 18 (14), 2648-2657, 2000 | 731 | 2000 |
| Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? R Adam, DA Wicherts, RJ de Haas, O Ciacio, F Lévi, B Paule, M Ducreux, ... Journal of Clinical Oncology 27 (11), 1829-1835, 2009 | 720 | 2009 |
| Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial T Ruers, F Van Coevorden, CJA Punt, JPEN Pierie, I Borel-Rinkes, ... JNCI: Journal of the National Cancer Institute 109 (9), djx015, 2017 | 647 | 2017 |
| Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin E Mitry, E Baudin, M Ducreux, JC Sabourin, P Rufié, T Aparicio, P Lasser, ... British journal of cancer 81 (8), 1351-1355, 1999 | 593 | 1999 |
| Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy D Elias, F Blot, A El Otmany, S Antoun, P Lasser, V Boige, P Rougier, ... Cancer 92 (1), 71-76, 2001 | 571 | 2001 |
| Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial G Pelletier, M Ducreux, F Gay, M Luboinski, H Hagège, D Thong, ... Journal of hepatology 29 (1), 129-134, 1998 | 527 | 1998 |
Sabourin jcProfesseur, anatomie pathologique, CHU de RouenVerified email at chu-rouen.fr
